Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination ...

Introduction Sodium-glucose cotransporter (SGLT) inhibitors have shown substantial benefit in reducing cardiovascular and kidney events across diverse clinical populations, but the underlying ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

Abstract: In traditional Chinese medicine, deciphering herb-symptom associations (HSAs) and revealing their mechanisms of action are crucial for bridging traditional knowledge and modern biomedicine.

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) ...

Zongertinib gained accelerated approval for unresectable/metastatic HER2 kinase-domain–mutant nonsquamous NSCLC, with 76% ORR and DOR ≥12 months in 44%. AMPLIFY ...

The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads to provide dual mechanisms of ...

Triple-negative breast cancer (TNBC), the most aggressive subtype, poses a significant challenge as approved targeted therapies are lacking. The epidermal growth factor receptor (EGFR) is highly ...